Last reviewed · How we verify
Sedatives/Hypnotics,Other
Sedatives/Hypnotics,Other is a Sedative/Hypnotic Small molecule drug developed by University of Oulu. It is currently FDA-approved for Insomnia, Anxiety disorders. Also known as: Dinitrous oxide.
Sedatives/hypnotics work by enhancing inhibitory neurotransmission in the central nervous system to promote sleep and reduce anxiety.
Sedatives/hypnotics are used to treat conditions such as sleep disorders, sleep problems, and sedation in intensive care units. They can be administered through various interventions, including exposure to sedative-hypnotic drugs, specific tapering plans, and educational and cognitive behavioral therapy elements.
At a glance
| Generic name | Sedatives/Hypnotics,Other |
|---|---|
| Also known as | Dinitrous oxide |
| Sponsor | University of Oulu |
| Drug class | Sedative/Hypnotic |
| Modality | Small molecule |
| Therapeutic area | Neurology/Psychiatry |
| Phase | FDA-approved |
Mechanism of action
This drug class typically acts on GABAergic or other inhibitory pathways in the brain to depress central nervous system activity. By enhancing the effect of inhibitory neurotransmitters, these agents reduce neuronal excitability, leading to sedation, anxiolysis, and sleep induction. The specific molecular target depends on the individual agent within this broad class.
Approved indications
- Insomnia
- Anxiety disorders
Common side effects
- Drowsiness/sedation
- Dizziness
- Dependence/tolerance
- Cognitive impairment
Key clinical trials
- Medical Phenotyping of NHS General Adult Psychiatry (GAP) Inpatients
- Study of Remimazolam for Cataract Surgery (PHASE4)
- A Comparative Study of Eleveld and Schnider Pharmacokinetic Models for Target-Controlled Infusion of Propofol in Sedation of Mechanically Ventilated ICU Patients
- Attempted Suicide Short Intervention Program for Older Adults (ASSIP-OA): An Evaluation of a Psychosocial Intervention for Suicidal Adults Aged 65+ (NA)
- National Pregnancy Registry for Psychiatric Medications
- Improving Patient Safety by Supporting Older Adults in Managing Sleep Problems. (NA)
- Intranasal Dexmedetomidine Sedation During Intra-articular Joint Injections in Pediatric Population (PHASE4)
- A Practical RCT of TCM in the Treatment of LCOVID and Analysis of Syndrome Types and Medication Characteristics. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sedatives/Hypnotics,Other CI brief — competitive landscape report
- Sedatives/Hypnotics,Other updates RSS · CI watch RSS
- University of Oulu portfolio CI
Frequently asked questions about Sedatives/Hypnotics,Other
What is Sedatives/Hypnotics,Other?
How does Sedatives/Hypnotics,Other work?
What is Sedatives/Hypnotics,Other used for?
Who makes Sedatives/Hypnotics,Other?
Is Sedatives/Hypnotics,Other also known as anything else?
What drug class is Sedatives/Hypnotics,Other in?
What development phase is Sedatives/Hypnotics,Other in?
What are the side effects of Sedatives/Hypnotics,Other?
Related
- Drug class: All Sedative/Hypnotic drugs
- Manufacturer: University of Oulu — full pipeline
- Therapeutic area: All drugs in Neurology/Psychiatry
- Indication: Drugs for Insomnia
- Indication: Drugs for Anxiety disorders
- Also known as: Dinitrous oxide
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing